Advances in Management of Moderate to Severe Atopic Dermatitis in Children and Adolescents
September 25, 2019
September 25, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This educational initiative has been designed for pediatricians, family physicians, nurse practitioners, and physician assistants involved in the management of children and adolescents with AD.
Atopic dermatitis (AD) and its associated comorbidities represent a significant healthcare burden due in large part to gaps in care and unmet medical needs pertaining to its diagnosis, assessment and treatment.
Difficulties associated with physician-patient-caregiver interaction that impacts patient adherence are common. Clinicians frequently assume that the information given during an office visit will be carried out appropriately. The identified limitations of physician communication with patients and caregivers, combined with the fact that families do not routinely feel comfortable with the management of their children’s skin disease highlights a critical gap in care of children and adolescents with AD.
Improving clinician-patient-caregiver communication is critical to ensure improved outcomes in AD. This program will provide strategies to engage patients in their care, including the use of a written action plan for AD. It will also review updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate symptom burden of AD and its severity.
Upon completion of this activity, participants should be better able to:
- Accurately diagnose and assess severity of disease in children and adolescents with AD
- Utilize guidelines to design treatment plans for patients with AD based on disease severity
- Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy
- Discuss efficacy and safety of biologic therapies for the management of patients with AD
Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Feinberg School of Medicine and Partner
Medical Dermatology Associates
Peck Y. Ong, MD
Associate Professor of Clinical Pediatrics
Department of Pediatrics
University of Southern California
Division of Clinical Immunology and Allergy
Children’s Hospital Los Angeles
Los Angeles, California
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Peter A. Lio, MD
- Consulting Fees: AbbVie; Eli Lilly and Company; Exeltis; Galderma Laboratories, LP; gpower, Inc.; Heel (Biologische Heilmittel Heel, GmbH); IntraDerm Pharmaceuticals; Johnson & Johnson Consumer Products; Kiniksa Pharmaceuticals, Ltd.; L’Oreal/La Roche Posay Laboratoire Dermatologique; Pfizer Inc.; Pierre-Fabre Dermatologie; Realm Therapeutics; Sanofi Genzyme and Regeneron Pharmaceuticals; Theraplex; TopMD; UCB; Unilever; Valeant Pharmaceuticals
- Speakers’ Bureaus: Galderma Laboratories, LP; La Roche Posay Laboratoire Dermatologique; Pfizer; Sanofi Genzyme and Regeneron Pharmaceuticals
- Contracted Research: AbbVie; AOBiome, LLC; Sanofi Genzyme and Regeneron Pharmaceuticals
- Ownership Interests: Altus Labs/Franklin BioScience; DermVeda; Syncere Skin Systems; Theraplex
Peck Y. Ong, MD
- Consulting Fees: AbbVie; Pfizer Inc.
- Contracted Research: Regeneron Pharmaceuticals
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of September 24, 2019 through September 24, 2020, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or email@example.com.
If you have any questions relating to your certificate or other issues with this activity, please contact FreeCME firstname.lastname@example.org.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.